scholarly journals Elevated Levels of Plasma IgA Autoantibodies against Oxidized LDL Found in Proliferative Diabetic Retinopathy but Not in Nonproliferative Retinopathy

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Satu Vavuli ◽  
Tuire Salonurmi ◽  
Sirpa Loukovaara ◽  
Antti E. Nissinen ◽  
Markku J. Savolainen ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Proliferative Diabetic Retinopathy ◽  
Oxidized Ldl ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 1 Diabetic Patients ◽  
Type 2 Diabetic

Aims. This study investigated the association of autoantibodies binding to oxidized low-density lipoproteins (oxLDL) in diabetic retinopathy (DR). Methods. Plasma from 229 types 1 and 2 patients with DR including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) was analysed with ELISA-based assay to determine IgA, IgG, and IgM autoantibody levels binding to oxLDL. The controls were 106 diabetic patients without retinopathy (NoDR) and 139 nondiabetic controls (C). Results. PDR group had significantly higher IgA autoantibody levels than DME or NoDR: mean 94.9 (SD 54.7) for PDR, 75.5 (41.8) for DME (p=0.001), and 76.1 (48.2) for NoDR (p=0.008). There were no differences in IgG, IgM, or IgA that would be specific for DR or for DME. Type 2 diabetic patients had higher levels of IgA autoantibodies than type 1 diabetic patients (86.0 and 65.5, resp., p=0.004) and the highest levels in IgA were found in type 2 diabetic patients with PDR (119.1, p>0.001). Conclusions. IgA autoantibodies were increased in PDR, especially in type 2 diabetes. The high levels of IgA in PDR, and especially in type 2 PDR patients, reflect the inflammatory process and enlighten the role of oxLDL and its autoantibodies in PDR.

Evaluating the role of serum apolipoprotein B to serum apolipoprotein A ratio in type 2Egyptian diabetic patient with retinopathy

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Salwa Seddik Hosny ◽  
Merhan Samy Nasr ◽  
Rana Hashem Ibrahim ◽  
Moata zM. W AbdElfattah ◽  
Samar Helmy Abdel Dayem Abdel Razek
Keyword(s):  
Diabetic Retinopathy ◽  
Diabetic Patient ◽  
Proliferative Diabetic Retinopathy ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Apo B ◽  
Apolipoprotein A ◽  
Type 2 Diabetic

Abstract Background Diabetes mellitus (DM) has routinely been described as a metabolic disorder characterized by hyperglycemia that develops as a consequence of defects in insulin secretion, insulin action, or both. Type 2 Diabetes encompasses individuals who have insulin resistance (IR) and usually relative (rather than absolute) insulin deficiency. The pathologic hallmark of DM involves the vasculature leading to both micro vascular and macro vascular complications. Diabetic retinopathy (DR) is a chronic progressive, potentially sight-threatening disease of the retinal microvasculature associated with the prolonged hyperglycemia and other conditions linked to diabetes mellitus such as hypertension. Legal blindness due to DR is estimated to be 25 times more common among the diabetic population than in those without diabetes Objective To evaluate the role of novel serum lipid markers (serum apolipoprotein B to serum apolipoprotein A ratio) in various grades of diabetic retinopathy . Methods This study was conducted on 80 type 2 diabetic patients. Their age between 40-70 years old. There were collected from outpatient ophthalmology clinic at el Demerdash hospital, it was conducted from March to September, 2018. The study was explained to all patients and control subjects, and consent was obtained from them before starting the study. They were subdivided into 3 groups; type 2 diabetic patients with proliferative diabetic retinopathy (group I), type 2 diabetic patients with non-proliferative diabetic retinopathy (group II) and type 2 diabetic patients without retinopathy as control group (group III). Results Our results showed that the serum apo B to serum apo A ratio is higher in the diabetic patient with proliferative diabetic retinopathy than the diabetic patient with non-proliferative diabetic retinopathy. Which is higher than the diabetic patient without retinopathy. Drawing attention to the possible relationship between the serum apo B to serum apo A ratio and the progression of diabetic retinopathy. Conclusion We found that the serum apo B to serum apo A ratio is higher in the diabetic patient with proliferative diabetic retinopathy than the diabetic patient with non-proliferative diabetic retinopathy. Which is higher than the diabetic patient without retinopathy. Drawing attention to the possible relationship between the serum apo B to serum apo A ratio and the progression of diabetic retinopathy. We found a highly significant difference regarding triglycerides, total cholesterol, Apo B and B/A ratio being higher in diabetic patient with proliferative diabetic retinopathy than diabetic patient with non- proliferative diabetic retinopathy and diabetic patient without retinopathy suggesting the relation between these factors and the progression of diabetic retinopathy. We found that hypertension duration is the most independent factor affecting B/A ratio. So lowering blood pressure can decrease retinopathy progression and improve prognosis in people with type 2 diabetes especially in the first 4- 5 years.

scholarly journals Serum IL-17, IL-23, and TGF-βLevels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Azam Roohi ◽  
Mina Tabrizi ◽  
Farzaneh Abbasi ◽  
Asal Ataie-Jafari ◽  
Behrouz Nikbin ◽  
...  
Keyword(s):  
Serum Levels ◽  
Diabetic Patients ◽  
Low Grade ◽  
Healthy Controls ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Type 1 Diabetic Patients ◽  
Type 2 Diabetic

Type 1 diabetes is recognized as an autoimmune inflammatory disease and low grade inflammation is also observed in type 2 diabetic patients. Interleukin 17 (IL-17) is a new player in inflammation. Th17 cells, as the main source of IL-17, require transforming growth factorβ(TGF-β) and interleukin 23 (IL-23). The aim of this study was to investigate serum IL-17, IL-23 and TGF-βlevels in diabetic patients and controls. In this case-control study, serum levels of IL-17, IL-23, and TGF-βwere measured in 24 type 1 diabetic patients and 30 healthy controls using the ELISA method. Simultaneously, the same methodology was used to compare serum concentration of these three cytokines in 38 type 2 diabetic patients and 40 healthy controls. There was no significant difference between serum levels of IL-17 and IL-23 cytokines between cases and controls. However, TGF-βwas significantly lower in type 1 diabetic patients (P<0.001). Serum IL-17 and IL-23 levels demonstrate no association with type 1 and type 2 diabetes, but, in line with previous studies, TGF-βlevels were lower in type 1 diabetic patients.

scholarly journals Serum Interleukin-18 Levels are Not Increased in Type 2 Diabetic Patients

2020 ◽  
Author(s):  
Xuejiao Li ◽  
Shuo Zhang ◽  
Chang Liu ◽  
Zhuoshi Wang ◽  
Peng Zhang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Retinopathy ◽  
Proliferative Diabetic Retinopathy ◽  
Fasting Blood Glucose ◽  
Diabetic Patients ◽  
Interleukin 18 ◽  
Normal Range ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Abstract Background: To investigate the effects of interleukin 18 (IL-18) on diabetic retinopathy (DR) of type 2 diabetic patients, the contents of IL-18 were measured in serum of 206 case subjects with type 2 diabetes and 40 case subjects without diabetes as control. Methods: According to the degree of DR, the diabetic patients were further divided into three groups: non-diabetic retinopathy (NDR, n=69), non-proliferative diabetic retinopathy (NPDR, n = 52) and proliferative diabetic retinopathy (PDR, n=85). Results: Unlike previous reports, we didn’t found a significant increase in serum IL-18 level in diabetic patients (mean ± SD are 107.4±36.6 and 112.5±32.0 pg/ml for control and type 2 diabetes patients respectively, p > 0.05). Further analysis also failed to found any significant increase of serum IL-18 in patients with NDR, NPDR or PDR (113.0±32.1, 110.8±31.4 and 114.5±33.4 pg/ml respectively) when compared with control (for all values, p > 0.05). Real-time qPCR suggests that the expression of IL-18 mRNA in type 2 diabetic patients with DR was comparable to that of controls (p>0.05). Interestingly, there was a significant positive correlation between levels of serum IL -18 and the amount of fasting blood glucose (FBG, r=0.15，p=0.03) and that Hemoglobin A1c (HbA1c) was relatively higher in diabetic patients than in control subjects (p<0.05). These results suggest that the levels of serum IL -18 in diabetic patients are within the normal range. Even in patients with diabetic retinopathy, the levels of serum IL -18 were only slightly increased in type 2 diabetic patients and was not statistically different from control subjects.Conclusion: these data suggest that the serum IL -18 levels are not associated with the severity of type 2 diabetic patients.

scholarly journals Type 2 Diabetic Patients with Nephropathy Show Structural—Functional Relationships that Are Similar to Type 1 Disease

2000 ◽  
Vol 11 (9) ◽  
pp. 1667-1673 ◽  
Author(s):  
KATHRYN ELIZABETH WHITE ◽  
RUDOLF WILLIAM BILOUS
Keyword(s):  
Creatinine Clearance ◽  
Volume Fraction ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Functional Relationships ◽  
Matrix Volume ◽  
Type 2 Diabetic

Abstract.Glomerular structural—functional relationships were investigated in 21 type 2 diabetic patients with proteinuria. Structural parameters were quantified using both light and electron microscopy and standard stereologic techniques. Data were also available on 14 nondiabetic subjects. Mesangial and matrix volume fractions and glomerular basement membrane (GBM) width were increased in type 2 patients when compared with nondiabetic subjects (mean ± SD: 0.45 ± 0.13versus0.18 ± 0.03,P< 0.001; 0.28 ± 0.09versus0.10 ± 0.02,P< 0.001; and 665 ± 138versus361 ± 51 nm,P< 0.001, respectively). An increase in mesangial volume fraction was associated with high levels of proteinuria and low creatinine clearance (r= 0.64,P= 0.002;r= -0.58,P= 0.006, respectively). GBM width and mesangial foot process width (FPWmes) also correlated with proteinuria (r= 0.58,P= 0.006;r= 0.60,P= 0.004, respectively). Volume fraction of interstitium correlated with creatinine clearance (r= -0.58,P= 0.006). Patients had previously been defined by light microscopy as having either diffuse or nodular glomerulosclerosis; those with nodules had larger mesangial and matrix volume fractions and more proteinuria than those classified as diffuse (mean ± SD: 0.51 ± 0.12versus0.36 ± 0.08,P= 0.007; 0.32 ± 0.08versus0.21 ± 0.05,P= 0.003; median, range: 4.3, 1.1 to 9.6versus1.1, 0.9 to 12.7 g/24 h,P= 0.027). Creatinine clearance did not differ significantly between the groups. Type 2 diabetic patients with proteinuria have established glomerulopathy, which is more advanced in those with nodular glomerulosclerosis. Creatinine clearance correlated with both mesangial and interstitial expansion, whereas proteinuria correlated only with glomerular pathology. These results suggest that type 2 patients with advanced nephropathy have structural—functional relationships similar to type 1, consistent with a common pathogenesis, and strongly support an important role of the tubulointerstitium in the role of renal impairment.

Sign in / Sign up

Export Citation Format

Share Document